Hopelessness as a predictor of non-response to fluoxetine in major depressive disorder

George I. Papakostas, Timothy Petersen, Caitlin H. Homberger, Cassandra H. Green, Juliana Smith, Jonathan E. Alpert, Maurizio Fava

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background. The purpose of this study was to study hopelessness as a predictor of response to fluoxetine in outpatients with Major Depressive Disorder (MDD). Methods. The degree of hopelessness was assessed during the baseline visit with the use of the Beck Hopelessness Scale (BHS) in 312 patients with MDD (56.1% women; 39.8 ± 10.3 years of age) who entered an 8-week, 20-mg, fixed-dose, open trial of fluoxetine. With the use of a logistic regression we tested whether BHS scores at baseline predicted clinical response, controlling for the severity of depression as reflected by the total score on the 17-item Hamilton Depression Rating Scale (HAM-D-17). With the use of a multiple regression we also tested whether BHS scores at baseline predicted HAM-D-17 scores at endpoint, controlling for HAM-D-17 scores at baseline. Results. After controlling for depression severity at baseline, a greater degree of hopelessness was found to significantly increase the risk of non-response to fluoxetine (p = 0.0413), as well as the risk of greater endpoint depression severity (p = 0.0305). Conclusions. Hopelessness appeared to be associated with poorer response to treatment with fluoxetine in MDD, and this was independent of depression severity. Similar studies involving treatment with higher doses of fluoxetine and for greater duration as well as a placebo comparator arm are needed to further explore the relationship between hopelessness, placebo response and drug response.

Original languageEnglish (US)
Pages (from-to)5-8
Number of pages4
JournalAnnals of Clinical Psychiatry
Volume19
Issue number1
DOIs
StatePublished - Jan 2007
Externally publishedYes

Fingerprint

Fluoxetine
Major Depressive Disorder
Depression
Placebos
Outpatients
Logistic Models
Therapeutics
Pharmaceutical Preparations

Keywords

  • Depression
  • Fluoxetine
  • Hopelessness
  • Predict
  • Response

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Hopelessness as a predictor of non-response to fluoxetine in major depressive disorder. / Papakostas, George I.; Petersen, Timothy; Homberger, Caitlin H.; Green, Cassandra H.; Smith, Juliana; Alpert, Jonathan E.; Fava, Maurizio.

In: Annals of Clinical Psychiatry, Vol. 19, No. 1, 01.2007, p. 5-8.

Research output: Contribution to journalArticle

Papakostas, George I. ; Petersen, Timothy ; Homberger, Caitlin H. ; Green, Cassandra H. ; Smith, Juliana ; Alpert, Jonathan E. ; Fava, Maurizio. / Hopelessness as a predictor of non-response to fluoxetine in major depressive disorder. In: Annals of Clinical Psychiatry. 2007 ; Vol. 19, No. 1. pp. 5-8.
@article{7237e137319447fa840803d31c91af8f,
title = "Hopelessness as a predictor of non-response to fluoxetine in major depressive disorder",
abstract = "Background. The purpose of this study was to study hopelessness as a predictor of response to fluoxetine in outpatients with Major Depressive Disorder (MDD). Methods. The degree of hopelessness was assessed during the baseline visit with the use of the Beck Hopelessness Scale (BHS) in 312 patients with MDD (56.1{\%} women; 39.8 ± 10.3 years of age) who entered an 8-week, 20-mg, fixed-dose, open trial of fluoxetine. With the use of a logistic regression we tested whether BHS scores at baseline predicted clinical response, controlling for the severity of depression as reflected by the total score on the 17-item Hamilton Depression Rating Scale (HAM-D-17). With the use of a multiple regression we also tested whether BHS scores at baseline predicted HAM-D-17 scores at endpoint, controlling for HAM-D-17 scores at baseline. Results. After controlling for depression severity at baseline, a greater degree of hopelessness was found to significantly increase the risk of non-response to fluoxetine (p = 0.0413), as well as the risk of greater endpoint depression severity (p = 0.0305). Conclusions. Hopelessness appeared to be associated with poorer response to treatment with fluoxetine in MDD, and this was independent of depression severity. Similar studies involving treatment with higher doses of fluoxetine and for greater duration as well as a placebo comparator arm are needed to further explore the relationship between hopelessness, placebo response and drug response.",
keywords = "Depression, Fluoxetine, Hopelessness, Predict, Response",
author = "Papakostas, {George I.} and Timothy Petersen and Homberger, {Caitlin H.} and Green, {Cassandra H.} and Juliana Smith and Alpert, {Jonathan E.} and Maurizio Fava",
year = "2007",
month = "1",
doi = "10.1080/10401230601163451",
language = "English (US)",
volume = "19",
pages = "5--8",
journal = "Annals of Clinical Psychiatry",
issn = "1040-1237",
publisher = "Dowden Health Media,Inc",
number = "1",

}

TY - JOUR

T1 - Hopelessness as a predictor of non-response to fluoxetine in major depressive disorder

AU - Papakostas, George I.

AU - Petersen, Timothy

AU - Homberger, Caitlin H.

AU - Green, Cassandra H.

AU - Smith, Juliana

AU - Alpert, Jonathan E.

AU - Fava, Maurizio

PY - 2007/1

Y1 - 2007/1

N2 - Background. The purpose of this study was to study hopelessness as a predictor of response to fluoxetine in outpatients with Major Depressive Disorder (MDD). Methods. The degree of hopelessness was assessed during the baseline visit with the use of the Beck Hopelessness Scale (BHS) in 312 patients with MDD (56.1% women; 39.8 ± 10.3 years of age) who entered an 8-week, 20-mg, fixed-dose, open trial of fluoxetine. With the use of a logistic regression we tested whether BHS scores at baseline predicted clinical response, controlling for the severity of depression as reflected by the total score on the 17-item Hamilton Depression Rating Scale (HAM-D-17). With the use of a multiple regression we also tested whether BHS scores at baseline predicted HAM-D-17 scores at endpoint, controlling for HAM-D-17 scores at baseline. Results. After controlling for depression severity at baseline, a greater degree of hopelessness was found to significantly increase the risk of non-response to fluoxetine (p = 0.0413), as well as the risk of greater endpoint depression severity (p = 0.0305). Conclusions. Hopelessness appeared to be associated with poorer response to treatment with fluoxetine in MDD, and this was independent of depression severity. Similar studies involving treatment with higher doses of fluoxetine and for greater duration as well as a placebo comparator arm are needed to further explore the relationship between hopelessness, placebo response and drug response.

AB - Background. The purpose of this study was to study hopelessness as a predictor of response to fluoxetine in outpatients with Major Depressive Disorder (MDD). Methods. The degree of hopelessness was assessed during the baseline visit with the use of the Beck Hopelessness Scale (BHS) in 312 patients with MDD (56.1% women; 39.8 ± 10.3 years of age) who entered an 8-week, 20-mg, fixed-dose, open trial of fluoxetine. With the use of a logistic regression we tested whether BHS scores at baseline predicted clinical response, controlling for the severity of depression as reflected by the total score on the 17-item Hamilton Depression Rating Scale (HAM-D-17). With the use of a multiple regression we also tested whether BHS scores at baseline predicted HAM-D-17 scores at endpoint, controlling for HAM-D-17 scores at baseline. Results. After controlling for depression severity at baseline, a greater degree of hopelessness was found to significantly increase the risk of non-response to fluoxetine (p = 0.0413), as well as the risk of greater endpoint depression severity (p = 0.0305). Conclusions. Hopelessness appeared to be associated with poorer response to treatment with fluoxetine in MDD, and this was independent of depression severity. Similar studies involving treatment with higher doses of fluoxetine and for greater duration as well as a placebo comparator arm are needed to further explore the relationship between hopelessness, placebo response and drug response.

KW - Depression

KW - Fluoxetine

KW - Hopelessness

KW - Predict

KW - Response

UR - http://www.scopus.com/inward/record.url?scp=33947318978&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947318978&partnerID=8YFLogxK

U2 - 10.1080/10401230601163451

DO - 10.1080/10401230601163451

M3 - Article

VL - 19

SP - 5

EP - 8

JO - Annals of Clinical Psychiatry

JF - Annals of Clinical Psychiatry

SN - 1040-1237

IS - 1

ER -